Abstract: A system for controlling a throttle signal, as well as methods of assembling the same, is provided. Controlling the throttle signal includes activating a supply of power to an electronic control unit (ECU). A first throttle signal associated with a throttle position signal of a vehicle throttle is communicated. An initial gear state of the vehicle is determined. Based on the initial gear state of the vehicle, a modified throttle signal to the ECU is communicated in response to receiving a command signal. Based on determining a change in the gear state of the vehicle, terminating the communication of the modified throttle signal. A second throttle signal that is associated with a second throttle position signal of the vehicle throttle is communicated.

Abstract: A computing system runs an application (e.g., video game) that interacts with one or more actively engaged users. One or more physical properties of a group are sensed. The group may include the one or more actively engaged users and/or one or more entities not actively engaged with the application. The computing system will determine that the group (or the one or more entities not actively engaged with the application) have performed a predetermined action. A runtime condition of the application is changed in response to determining that the group (or the one or more entities not actively engaged with the computer based application) have performed the predetermined action. Examples of changing a runtime condition include moving an object, changing a score or changing an environmental condition of a video game.

Abstract: Systems and methods for multi-platform motion interactivity, is provided. The system includes a motion-sensing subsystem, a display subsystem including a display, a logic subsystem, and a data-holding subsystem containing instructions executable by the logic subsystem. The system configured to display a displayed scene on the display; receive a dynamically-changing motion input from the motion-sensing subsystem that is generated in response to movement of a tracked object; generate, in real time, a dynamically-changing 3D spatial model of the tracked object based on the motion input; control, based on the movement of the tracked object and using the 3D spatial model, motion within the displayed scene. The system further configured to receive, from a secondary computing system, a secondary input; and control the displayed scene in response to the secondary input to visually represent interaction between the motion input and the secondary input.

Abstract: Systems and methods for multi-platform motion interactivity, is provided. The system includes a motion-sensing subsystem, a display subsystem including a display, a logic subsystem, and a data-holding subsystem containing instructions executable by the logic subsystem. The system configured to display a displayed scene on the display; receive a dynamically-changing motion input from the motion-sensing subsystem that is generated in response to movement of a tracked object; generate, in real time, a dynamically-changing 3D spatial model of the tracked object based on the motion input; control, based on the movement of the tracked object and using the 3D spatial model, motion within the displayed scene. The system further configured to receive, from a secondary computing system, a secondary input; and control the displayed scene in response to the secondary input to visually represent interaction between the motion input and the secondary input.

Abstract: A computing system runs an application (e.g., video game) that interacts with one or more actively engaged users. One or more physical properties of a group are sensed. The group may include the one or more actively engaged users and/or one or more entities not actively engaged with the application. The computing system will determine that the group (or the one or more entities not actively engaged with the application) have performed a predetermined action. A runtime condition of the application is changed in response to determining that the group (or the one or more entities not actively engaged with the computer based application) have performed the predetermined action. Examples of changing a runtime condition include moving an object, changing a score or changing an environmental condition of a video game.

Abstract: A camera that can sense motion of a user is connected to a computing system (e.g., video game apparatus or other type of computer). The computing system determines an action corresponding to the sensed motion of the user and determines a magnitude of the sensed motion of the user. The computing system creates and displays an animation of an object (e.g., an avatar in a video game) performing the action in a manner that is amplified in comparison to the sensed motion by a factor that is proportional to the determined magnitude. The computing system also creates and outputs audio/visual feedback in proportion to a magnitude of the sensed motion of the user.

Abstract: A computing system runs an application (e.g., video game) that interacts with one or more actively engaged users. One or more physical properties of a group are sensed. The group may include the one or more actively engaged users and/or one or more entities not actively engaged with the application. The computing system will determine that the group (or the one or more entities not actively engaged with the application) have performed a predetermined action. A runtime condition of the application is changed in response to determining that the group (or the one or more entities not actively engaged with the computer based application) have performed the predetermined action. Examples of changing a runtime condition include moving an object, changing a score or changing an environmental condition of a video game.

Abstract: Pyrrolidine compounds of Formula (I), (wherein R1, R2, R3, R4, R5, R6a, R6b, R7 and R8 are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: The present invention encompasses compounds of Formula (I) and pharmaceutically acceptable salts or hydrates thereof. The compounds are inhibitors of granzyme B and are useful for treating autoimmune and chronic inflammatory diseases. Pharmaceutical compositions and methods of use are also included.

Abstract: A method and apparatus for dispensing prepackaged medication packages includes an apparatus having a body with an internal cavity and an opening. A central processing unit operably communicates with an actuator and at least one sensor within the cavity to regulate and monitor the dispensation of the packages, while the actuator operably communicates with a feed mechanism within the cavity to dispense the packages.

Abstract: A method and apparatus for dispensing prepackaged medication packages includes an apparatus having a body with an internal cavity and an opening. A central processing unit operably communicates with an actuator within the cavity to regulate and monitor the dispensation of the packages, while the actuator operably communicates with a feed mechanism within the cavity to dispense the packages.

Abstract: Pyrrolidine compounds of Formula (I), (wherein R1, R2, R3, R4, R5, R6a, R6b, R7 and R8 are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Abstract: Pyrrolidine compounds of Formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, j, k, 1, m, and n are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Abstract: Pyrrolidine compounds of Formula I: 1

Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Abstract: Pyrrolidine compounds of Formula I: 1

Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Abstract: The present invention is directed to pyrrolidine compounds of the formula 1: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

Abstract: The present invention is directed to pyrrolidine and piperidine compounds of the formula I: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.4d, R.sup.4e, R.sup.4f, R.sup.4g, R.sup.4h, m, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.